Hepatocellular carcinoma (hcc) Clinical Trials
Conditions / Hepatocellular carcinoma (hcc)
Delta Trials records 180 clinical trials for Hepatocellular carcinoma (hcc) in its publicly accessible dataset. From the full dataset, 81 actively seeking eligible participants and 38 trials have reached completion. This research is conducted across 495 study locations around the world. An additional 61 trials are active but not currently open for enrollment. Since 2020, 8 trials have been stopped, reflecting shifts in research priorities or feasibility. The trial counts on this page reflect the most recent data ingested from ClinicalTrials.gov, with history tracked across multiple versions.
Trial Status
180
Total Trials
81
Recruiting
38
Completed
61
Other Active
8
Terminated since 2020
495
Study Locations
Browse by location (495 total)
- Shanghai, China 28 trialsAll trials in Shanghai, China
- Guangzhou, China 27 trialsAll trials in Guangzhou, China
- Beijing, China 21 trialsAll trials in Beijing, China
- Wuhan, China 18 trialsAll trials in Wuhan, China
- Seoul, South Korea 16 trialsAll trials in Seoul, South Korea
- Taipei, Taiwan 15 trialsAll trials in Taipei, Taiwan
- Taipei, Taiwan 15 trialsAll trials in Taipei, Taiwan
- Nanjing, China 15 trialsAll trials in Nanjing, China
- Hangzhou, China 14 trialsAll trials in Hangzhou, China
- Tainan, Taiwan 13 trialsAll trials in Tainan, Taiwan
- Hefei, China 13 trialsAll trials in Hefei, China
- Los Angeles, United States 11 trialsAll trials in Los Angeles, United States
- Harbin, China 11 trialsAll trials in Harbin, China
- Zhengzhou, China 10 trialsAll trials in Zhengzhou, China
- Tianjin, China 10 trialsAll trials in Tianjin, China
- London, United Kingdom 10 trialsAll trials in London, United Kingdom
- Boston, United States 9 trialsAll trials in Boston, United States
- Chengdu, China 9 trialsAll trials in Chengdu, China
- New York, United States 9 trialsAll trials in New York, United States
- Changchun, China 9 trialsAll trials in Changchun, China